Agreements reached under this partnership
Business alliance- 1
OEP will develop and commercialize the drug.
- 2
The Company will receive an upfront payment from OEP and milestone payments based on progress toward commercialization in Taiwan.
- 3
The Company will supply the drug product to OEP.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
The consolidated earnings forecast for the fiscal year ending March 2027, reflecting this transaction, is scheduled to be disclosed when the Company announces its financial results for the fiscal year ending March 2026 on 11 May 2026.
| Item | Details |
|---|---|
| Name of alliance partner | Orient EuroPharma Co., Ltd. |
| Alliance partner's business activities | Development and sale of pharmaceuticals, dietary supplements and beauty-related products. The company has particular strengths in oncology drugs and biologics, and sales channels not only in Taiwan but also in Southeast Asia and China. |
| Alliance partner's location | Taiwan |
| Type of alliance | Business alliance |
| Details of the alliance | OEP will develop and commercialize the drug., The Company will receive an upfront payment from OEP and milestone payments based on progress toward commercialization in Taiwan., The Company will supply the drug product to OEP. |
| Impact on Business Performance | The consolidated earnings forecast for the fiscal year ending March 2027, reflecting this transaction, is scheduled to be disclosed when the Company announces its financial results for the fiscal year ending March 2026 on 11 May 2026. |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Through collaboration with its partner, the Company aims to develop olutasidenib in the licensed territory and make it available at an early stage to patients with relapsed or refractory acute myeloid leukemia.